Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012. - Wikidata - wikimedia - TriplyDB

Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012.

Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012.

http://www.wikidata.org/entity/Q38123116

about

Hyperuricaemia with deposition: latest evidence and therapeutic approach Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy.Allopurinol: insights from studies of dose-response relationships.Genotyping for severe drug hypersensitivity.Effects of Modified Simiao Decoction on IL-1 β and TNF α Secretion in Monocytic THP-1 Cells with Monosodium Urate Crystals-Induced Inflammation.Transient hypofibrinogenemia due to allopurinol.Allopurinol hypersensitivity syndrome in patients with hematological malignancies: characteristics and clinical outcomes.Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study.Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study.Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview.Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis Validation of a Rapid, Robust, Inexpensive Screening Method for Detecting the HLA-B*58:01 Allele in the Prevention of Allopurinol-Induced Severe Cutaneous Adverse Reactions.The Effects of Modified Simiao Decoction in the Treatment of Gouty Arthritis: A Systematic Review and Meta-Analysis.Clinical manifestations of tension pneumothorax: protocol for a systematic review and meta-analysis.Pharmacokinetics considerations for gout treatments.Febuxostat for the treatment of gout.Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol.Allopurinol hypersensitivity: investigating the cause and minimizing the risk.Diagnostic utility of HLA-B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis.Advances in the Pharmacogenomics of Adverse Drug Reactions.Allopurinol induces innate immune responses through mitogen-activated protein kinase signaling pathways in HL-60 cells.Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome and the Rheumatologist.Severe Delayed Cutaneous and Systemic Reactions to Drugs: A Global Perspective on the Science and Art of Current Practice.Published cases of adverse drug reactions: has the quality of reporting improved over time?Cost-effectiveness analysis of genotyping for HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore.Hypouricemic effect and safety of febuxostat used for prevention of tumor lysis syndrome.Allopurinol-Induced Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome: A Cause of Acalculous Cholecystitis?Comparison between the HLA-B∗58 : 01 Allele and Single-Nucleotide Polymorphisms in Chromosome 6 for Prediction of Allopurinol-Induced Severe Cutaneous Adverse Reactions.Stevens-Johnson syndrome/toxic epidermal necrolysis and erythema multiforme drug-related hospitalisations in a national administrative database.PSORS1C1 Hypomethylation Is Associated with Allopurinol-Induced Severe Cutaneous Adverse Reactions during Disease Onset Period: A Multicenter Retrospective Case-Control Clinical Study in Han Chinese.How to prevent allopurinol hypersensitivity reactions?Fluoroquinolones and propionic acid derivatives induce inflammatory responses in vitro.Langfassung zur S2e-Leitlinie Gichtarthritis (fachärztlich)

P2860

Q26775759-9089DDB8-BD32-45B4-9B35-9291F57AB237 Q27692095-739E3097-26B1-4461-BD52-99E43CDB829D Q30240163-C1F83C2C-FCD7-4453-9208-66DEB6586B57 Q33582530-843D4046-2082-4250-AEEF-F00E62C35968 Q33796686-7FFF93BD-F4EE-4A79-A1EC-C16CCF342318 Q34155680-150C353B-3E45-4C37-BED6-D0ADB154C23B Q35834966-C32DADBA-4472-40E5-8742-A6130CB9E9E6 Q36085404-5E2B9639-FED5-494F-87F5-39BBBAC58315 Q36981450-D462CADD-6DEC-44FE-AC73-A32FEA20BC7A Q37127097-4FBB6217-C5C6-4FEB-B4CE-47ED3C963EA4 Q37240086-0155B392-16FC-4AEC-A022-A55B7B3C0C75 Q37404888-1F27A9C4-C8B9-4CB6-84F4-2B303FFC1B32 Q37714701-F67684E0-1327-4F07-98F9-2F8AAA624897 Q38175434-1C61F18F-43B7-4CCE-8EDE-122833A8BCD0 Q38210284-F874A232-31E1-44E4-8881-8064519849A8 Q38306517-BF302E8A-8376-41A7-8B61-43B5AC967490 Q38394345-B2DE084D-1FC1-47AA-8B1F-E23540FA20BA Q38594891-3B454406-037E-45BA-99C5-A5868700B6D8 Q38600529-5609F1FF-01B2-4AF6-8D6B-9394EBE31B6D Q38663764-B404A651-32C9-441D-B247-CA35FD144D0D Q38814020-B07426F6-BF92-469A-8442-9916670A66B7 Q39110729-F08DFC27-8132-4B2E-AC5B-B11752D68E28 Q39291741-62484657-C124-4FEE-8080-F50DC60C923B Q39884751-22E957DE-2FBA-465F-B96D-57403A202977 Q40915728-C548A7B6-019F-4ED3-B631-55B663A6AA4F Q42878232-19E124D7-8BF8-40CD-93E0-0C824C900807 Q47094238-791EB5F9-97F1-421A-B424-D8C24C06B4D3 Q48119431-81449888-8983-4E46-93D3-ED426D9B0292 Q48129701-00F52BDC-736E-429F-9206-8B1BDC414EFE Q49247755-F0EC72EA-496F-4AAF-821E-C618B64D77DF Q49616100-D5DD4EB8-FC51-433D-A374-8F4A75CE73DE Q51101396-6B6348FD-4741-4DC5-8D4A-F7649E770A5A Q56637250-F71D14DA-8028-41AD-A04E-84282731069B

P2860

Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012.

http://www.wikidata.org/entity/Q38123116

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012.

@en

type

label

Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012.

@en

prefLabel

Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012.

@en

P1433

Q38123116-FC712F40-8C9B-428B-9371-8A69E1BD781C

P1476

Q38123116-D1B907A2-A47C-4CE7-BAD0-8B6E33C264FC

P2093

Q38123116-19FD7991-929D-4689-B0E9-0FC7D6542DF7

Q38123116-7A655182-F500-47B5-97CB-ED16FB1081F1

Q38123116-7E0D81C3-4EE0-4EA3-A09F-CD81A0050BFA

Q38123116-85261C73-1562-4777-AECB-265AC8E9BC21

Q38123116-B60F750B-8DE4-429E-8349-09237AA8952B

Q38123116-CE6E5296-0EF0-4B36-B622-91354B32A05C

P2860

Q38123116-02070290-5B41-492A-A526-9B9B7C3E8964

Q38123116-05E51F39-0E47-470E-A13B-732799CE6BDE

Q38123116-07E64F17-8A41-44B6-878F-B555937DF229

Q38123116-08B51778-029C-40F3-BF01-50BB9FF97650

Q38123116-08B5A837-C32E-4DD7-8C68-6166E5C28808

Q38123116-0C8C77C9-8B38-41B0-BE1B-776F8419F18C

Q38123116-0D256530-8335-4CF9-B099-DFAA408BACE3

Q38123116-0D38129D-06D5-4F20-AD0C-E9151F99260A

Q38123116-0E36CEFE-3463-4010-A0DE-7D6048ACB246

Q38123116-0EB4A8D2-210E-4F39-AA98-1AD349D0E546

P2888

Q38123116-C5450C37-D98A-4F88-98B2-57D1DA693159

P304

Q38123116-8441B081-D9E2-476E-8D26-3A32633DE5F5

P31

Q38123116-B810D1B9-5873-418F-A175-1540950251F5

P356

Q38123116-568C0841-DDF0-48EF-A16D-062FA4FA724F

P433

Q38123116-2C339640-2ED7-43C0-8036-823C0A0A2A05

P478

Q38123116-87094AEA-2D21-447B-9425-BBF5567E33B7

P50

Q38123116-2127B73D-DF83-450A-B36F-E64726C3DEEF

Q38123116-A1DE97A2-7E69-49D6-B39D-ADC571B7B116

Q38123116-CF1C4C11-CBA7-447B-A35E-9AFFD71C8168

P577

Q38123116-D6A25E48-B2F5-4075-8CFD-56C841C14749

P6179

Q38123116-DE58ECE8-648E-4A85-9B13-6E5A8C2579F3

P698

Q38123116-6FADE8F6-B889-4953-8C70-E2ADA66E5388

P356

S40264-013-0084-0

P1433

P1476

Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012

@en

P2093

Cameron S Korb-Wells

http://www.w3.org/2001/XMLSchema#string

Garry G Graham

http://www.w3.org/2001/XMLSchema#string

Kenneth M Williams

http://www.w3.org/2001/XMLSchema#string

Myles W H Smith

http://www.w3.org/2001/XMLSchema#string

Nan Wang

http://www.w3.org/2001/XMLSchema#string

Sheena N Ramasamy

http://www.w3.org/2001/XMLSchema#string

P2860

Toxic epidermal necrolysis and Stevens-Johnson syndrome

The Link between Hypersensitivity Syndrome Reaction Development and Human Herpes Virus-6 Reactivation

Anecdotes as evidence

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol

A new equation to estimate glomerular filtration rate

Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol

Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout

Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis

Drug reaction with Eosinophilia and Systemic Symptoms (DRESS) / Drug-induced Hypersensitivity Syndrome (DIHS): a review of current concepts

Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting

P2888

s40264-013-0084-0

P304

953-980

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40264-013-0084-0

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P50

Diluk Kannangara

Darren M Roberts

P577

2013-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1043141260

http://www.w3.org/2001/XMLSchema#string

P698

23873481

http://www.w3.org/2001/XMLSchema#string